首页 | 本学科首页   官方微博 | 高级检索  
检索        


An Analysis of 5-Level Version of EQ-5D Adjusting for Treatment Switching: The Case of Patients With Epidermal Growth Factor Receptor T790M-Positive Nonsmall Cell Lung Cancer Treated With Osimertinib
Institution:1. PHMR Limited, Berkeley Works, London, England, UK;2. Department of Health Services Research and Policy, The Australian National University, Canberra, Australia;3. AstraZeneca Limited, Cambridge, England, UK;4. Centre for Health Policy, University of Melbourne, Parkville, Australia;1. Real World Solutions, IQVIA, London, England, UK;2. Real World Solutions, IQVIA, The Netherlands;3. Faculty of Epidemiology and Population, London School of Hygiene and Tropical Medicine, London, England, UK;4. Department of Health Policy, London School of Economics and Political Science, London, England, UK;5. EMEA Centre of Excellence for Retrospective Studies, IQVIA, London, England, UK;2. Global Access, F. Hoffmann-La Roche, Basel, Switzerland;1. PHMR, London, England, UK;3. Cytel, London, England, UK;4. Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada;1. Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, Canada;2. Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada;3. Joint Centre for Bioethics, University of Toronto, Toronto, Ontario, Canada;4. Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada;5. Department of Medicine, University of Toronto, Toronto, Ontario, Canada;6. Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada;1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada;2. Department of Public Health Sciences, Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;3. University of Toronto, Toronto, ON, Canada;4. Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada;5. Cancer Care Ontario, Toronto, ON, Canada;1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada;2. University of Toronto, Toronto, Ontario, Canada;3. Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada;4. Cancer Care Ontario, Toronto, Ontario, Canada
Abstract:
Keywords:EQ-5D  health economics  quality adjusted life years  quality of life  treatment switching
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号